- Home
- SCNX vs PRPO Comparison
SCNX vs PRPO Comparison
Compare SCNX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- PRPO
- Stock Information
- Founded
- SCNX 2010
- PRPO N/A
- Country
- SCNX United States
- PRPO United States
- Employees
- SCNX N/A
- PRPO N/A
- Industry
- SCNX Other Pharmaceuticals
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- SCNX Health Care
- PRPO Industrials
- Exchange
- SCNX Nasdaq
- PRPO Nasdaq
- Market Cap
- SCNX 31.5M
- PRPO 32.4M
- IPO Year
- SCNX 2020
- PRPO N/A
- Fundamental
- Price
- SCNX $0.59
- PRPO $22.69
- Analyst Decision
- SCNX
- PRPO
- Analyst Count
- SCNX 0
- PRPO 0
- Target Price
- SCNX N/A
- PRPO N/A
- AVG Volume (30 Days)
- SCNX 16.4M
- PRPO 13.2K
- Earning Date
- SCNX 11-13-2025
- PRPO 11-14-2025
- Dividend Yield
- SCNX N/A
- PRPO N/A
- EPS Growth
- SCNX N/A
- PRPO N/A
- EPS
- SCNX N/A
- PRPO N/A
- Revenue
- SCNX $653,391.00
- PRPO $22,800,000.00
- Revenue This Year
- SCNX N/A
- PRPO N/A
- Revenue Next Year
- SCNX N/A
- PRPO N/A
- P/E Ratio
- SCNX N/A
- PRPO N/A
- Revenue Growth
- SCNX 207.88
- PRPO 30.95
- 52 Week Low
- SCNX $0.46
- PRPO $3.90
- 52 Week High
- SCNX $8.72
- PRPO $28.50
- Technical
- Relative Strength Index (RSI)
- SCNX 44.06
- PRPO 59.62
- Support Level
- SCNX $0.50
- PRPO $22.00
- Resistance Level
- SCNX $0.62
- PRPO $28.50
- Average True Range (ATR)
- SCNX 0.06
- PRPO 1.64
- MACD
- SCNX -0.00
- PRPO 0.21
- Stochastic Oscillator
- SCNX 31.62
- PRPO 55.00
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.